The concept of control of COPD in clinical practice

International Journal of COPD

Volumn 9, Issue , 2014, Pages 1397-1405

  Soler Cataluña, Juan José ^a,b   Alcázar Navarrete, Bernardino ^c   Miravitlles, Marc ^b,d  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital de Alta Resolución de Guadix   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

CAT; CCQ; Control; COPD; Exacerbations; Prognosis

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL COPD QUESTIONNAIRE; CLINICAL PRACTICE; COLOR; COPD ASSESSMENT TEST; DETERIORATION; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; HUMAN; PHYSICAL ACTIVITY; QUESTIONNAIRE; SPUTUM; CONVALESCENCE; DISEASE COURSE; LUNG; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; LUNG; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84919432958     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S71370     Document Type: Article

References (48)

1. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68(7):687-690.
2. Miravitlles M, Soler-Cataluña JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41(6):1252-1256.
3. McDonald V, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68(7):691-694.
4. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish Guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50 Suppl 1: 1-16.
5. Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(2):189-201.
6. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598-604.
7. Celli BR, Cote CG, Marín JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012.
8. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103(5): 692-699.
9. Marín JM, Carrizo SJ, Casanova C, et al. Prediction of risk of COPD exacerbations by the BODE index. Respir Med. 2009;103(3): 373-378.
10. Soler-Cataluña JJ, Alcazar-Navarrete B, Miravitlles M. The concept of control in COPD: A New proposal for optimising therapy. Eur Respir J. 2014;44(4):1072-1075.
11. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2014. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf. Accessed November 13, 2014.
12. Guía española para el manejo del asma (GEMA 2009) [Spanish Guideline on the Management of Asthma]. Arch Bronconeumol. 2009; 45(Suppl 7):2-35. Spanish.
13. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836-844.
14. Cazzoletti L, Marcon A, Janson C, et al. Asthma control in Europe: A real-world evaluation based on an international population-based study. J Allergy Clin Immunol. 2007;120(6):1360-1367.
15. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J. 2008;31(2):320-325.
16. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532-555.
17. Agustí A, Calverley PMA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
18. Davis SQ, Permutt Z, Permutt S, et al. Perception of airflow obstruction in patients hospitalized for acute asthma. Ann Allergy Asthma Immunol. 2009;102(6):455-461.
19. Miravitlles M, Ferrer J, Baró E, Lleonart M, Galera J. Differences between physician and patient in the perception of symptoms and severity in COPD. Respir Med. 2013;107(12):1977-1985.
20. Jones P, Miravitlles M, van der Molen T, Kulich K. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement using a new generation of instruments. Int J Chron Obst Pulm Dis. 2012;7:697-709.
21. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Wur Respir J. 2009;34(3):648-654.
22. Van der Molen T, Willemse BWM, Schokker S, ten Hacken NHT, Postma DJ, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes. 2003;1:13.
23. Agustí A, Soler JJ, Molina J, et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD. 2012;9(5):492-498.
24. Miravitlles M. García-Sidro P, Fernández-Nistal A, Buendía MJ, Espinosade los Monteros MJ, Molina J. Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:147.
25. Oxford Dictionaries. Available from: http://www.oxforddictionaries.com/. Accessed October 16, 2014.
26. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195-203.
27. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006;7:62.
28. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29(3):527-534.
29. Soler-Cataluña JJ, Rodriguez-Roisin R. Frequent chronic obstructive p8lmonary disease exacerbators: how much real, how much fictitious? COPD. 2010;7(4):276-284.
30. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161(5):1608-1613.
31. Spencer S, Jones PW; GLOBE study group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58(7):589-593.
32. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67(3):238-243.
33. Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarkers(s) for disease activity needed-urgently. Am J Respir Crit Care Med. 2010;182(7):863-864.
34. Carter RI, Stockley RA. Disease “activity”, “severity” and “impact”: interrelationships in COPD; is a measure of disease “activity” the Holy Grail for COPD, or a variable impossible to quantify? COPD. 2014;11(4):363-367.
35. Tumkaya M, Atis S, Ozge C, Delialioglu N, Polat G, Kanik A. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med. 2007;101(4):729-737.
36. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759-764.
37. Thomsen M, Ingebrigtsen TS, Marrott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309(22):2353-2361.
38. Agustí A, Edwards LD, Rennard S., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. Plos One. 2012;7(5):e37483.
39. García-Polo C, Alcázar-Navarrete B, Ruiz-Iturriaga LA, et al. Factors associated with high resource utilisation among COPD patients. Respir Med. 2012;106(12):1734-1742.
40. García-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772-778.
41. Miravitlles M, Cantoni J, Naberan K. Factors associated with low level of physical activity in patients with chronic obstructive pulmonary disease. Lung. 2014;192(2);259-265.
42. Sundh J, Janson C, Lisspers K, Montgomery S, Ställberg B. Clinical COPD Questionnaire score (CCQ) and mortality. Int J Chron Obstruct Pulmon Dis. 2012;7:833-842.
43. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12): 1128-1138.
44. Miravitlles M, Sicras A, Crespo C, et al. Costs of COPD in relation to compliance with guidelines. A study in the Primary Care setting. Ther Adv Respir Dis. 2013;7(3):139-150.
45. Ghattas C, Dai A, Gemmel DJ, Award MH. Over diagnosis of chronic obstructive pulmonary disease in an underserved patient population. Int J Chron Obst Pulm Dis. 2013;8:545-549.
46. Al-Kassimi FA, Alhamad EH, Al-Hajjaj MS, Abba AA, Raddaoui E, Shaikh SA. Abrupt withdrawal of inhaled corticosteroids does not result in spirometric deterioration in chronic obstructive pulmonary disease: effect of phenotyping? Ann Thorac Med. 2012;7(4): 240-242.
47. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPS - a systematic review and comment of trial methodology. Respir Res. 2011;12:107.
48. Lopez-Campos JL, Bustamante V, Muñoz X, Barreiro E. Moving towards patient-centered medicine for COPD management: multidimensional approaches versus phenotype-based medicine - A critical view. COPD. 2014;11(5):591-602.